预约演示

Anivive to Present Groundbreaking Research on First Systemic Antifungal Vaccine at World Vaccine Congress

2024-04-04

疫苗临床研究

WASHINGTON, April 4, 2024 /PRNewswire/ -- Anivive Lifesciences, is set to unveil groundbreaking research at the upcoming World Vaccine Congress, where they will present findings on the development of the world's first systemic antifungal vaccine – A solution for both ends of the leash. The conference, taking place April 1-4, brings together leading experts and researchers from top scientists and life science companies around the globe to discuss advancements in vaccine development.

Post this

World Vaccine Congress

Dr. Edward Robb, Chief Strategy Officer at Anivive will present for the team and focus on the critical need for effective antifungal vaccines, particularly in light of rising fungal infections worldwide and the challenges associated with developing a fungal vaccine. This collaborative effort, crossing public and private enterprises has delivered a significant breakthrough in the field of vaccinology and holds the potential to be a first to prevent a systemic fungal infection common to both dog and man.

Fungal infections pose a serious threat to Anivivehealth, especially among immunocompromised individuals and those with underlying health conditions. Traditional treatment optfungal infectionse lengthy and costly therapies, with the risk of relapse and drug resistance. An antifungal vaccine offers a promising alternative by harnessing the body's immune system to prevent infection altogether.systemic fungal infection

Fungal infectionsxtensive experience in vaccinology spans decades, leads a dedicated team of researchers at Anivive and collaboration with the Valley Fever Center for Excellence at the University of Arizona. Their collaborative efforts have culminated in the development of a novel vaccine candidate that targets coccidioidomycosis fungal infections. A more common name Is infectionver.

The presentation by Dr. Robb will provide insights into the vaccine's mechanism of action, preclinical studiAnivivenstrating efficacy, and micrValley Fever for this first systemic antifUniversity of Arizonaees can expect to gain valuable knowledge about the challenges and opportunities in antifungal vaccine devecoccidioidomycosis fungal infectionstion of this pioneering Valley Fever

"We are at a pivotal moment in the fight against fungal infections," says Dr. Robb. "The development of an antifungal vaccine represents a transformative approach to combating these pervasive and often overlooked pathogens. I am honored to share our findings at the World Vaccine Congress and contribute to the global dialogue on vaccine innovation."

The World Vaccine Congress serves as a premier plfungal infectionsg cutting-edge research and fostering collaboration among experts in the field of vaccinology. Dr. Robb's presentation addresses how supporting One Health can meet unmet medical needs by aligning animal, human and environmental health, and how this novel antifungal Valley Fever vaccine supports health on both ends of the leash.

For more information about Dr. Robb's presentation and the World Vaccine Congress, please visit Anivive.comantifungal Valley Fever vaccine antifungal Valley Fever

About Anivive Lifesciences

AnivivAnivive Lifesciencestical company at the intersection of biotech, AI, software, and veterinary medicine. Our proprietary software platform accelerates the development of new, affordable treatments for life-threatening diseases in pets. Anivive's pipeline includes 8+ first-in-class therapeutics for three critical areas: Oncology, Anti-Virals and Anti-Fungal Vaccines. To learn more visit www.anivive.com

AniviveAnivive Lifesciences Inc.Anivive

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构